Dexcom's Stelo Brings Glucose Monitoring to Type 2 Patients Without Prescription

Dexcom's Stelo continuous glucose monitor became available over-the-counter in August 2024 following FDA approval. Unlike prescription CGMs, Stelo targets type 2 diabetics who don't use insulin—a far larger population than existing devices serve. The shift moves real-time glucose tracking from medical necessity into consumer health awareness, fundamentally expanding the addressable market for diabetes device makers.